Cargando…
Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD
Asthma and chronic obstructive pulmonary disease (COPD) are among the most common chronic diseases worldwide, characterized by a condition of variable degree of airway obstruction and chronic airway inflammation. A large body of evidence has demonstrated the importance of small airways as a pharmaco...
Autores principales: | Scichilone, Nicola, Benfante, Alida, Morandi, Luca, Bellini, Federico, Papi, Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251568/ https://www.ncbi.nlm.nih.gov/pubmed/25473323 http://dx.doi.org/10.2147/PROM.S55276 |
Ejemplares similares
-
Extrafine inhaled corticosteroid therapy in the control of asthma
por: Ivancsó, István, et al.
Publicado: (2013) -
Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial
por: Zheng, Jinping, et al.
Publicado: (2021) -
Predictors of clinical response to extrafine and non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma
por: Gafar, Fajri, et al.
Publicado: (2018) -
Asthma control in patients receiving inhaled corticosteroid and long-acting beta(2)-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation
por: Müller, Veronika, et al.
Publicado: (2011) -
Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids
por: Postma, Dirkje S., et al.
Publicado: (2017)